Commentaries
Craving,
prayer, and the brain
Dara G. Ghahremani PhD
Pages: 1-3 | DOI: 10.1080/00952990.2016.1200061
It’s
time to take psilocybin seriously as a possible treatment for substance use disorders
Michael P. Bogenschutz MD
Pages: 4-6 | DOI: 10.1080/00952990.2016.1200060
Review
Immune
activation and neuroinflammation in alcohol use and HIV infection: evidence for shared mechanisms
Mollie A. Monnig PhD
Pages: 7-23 | DOI: 10.1080/00952990.2016.1211667
Original Articles
Meta-analyses
of clinical neuropsychological tests of executive dysfunction and impulsivity in alcohol use disorder
Rick A. Stephan PhD, Omar M. Alhassoon PhD, Kenneth E. Allen PhD, Scott C. Wollman MA, Matt Hall MA, William J. Thomas PhD, Julia M. Gamboa PhD, Chrissy Kimmel MA, Mark Stern MA, Celina Sari MSc, Constance J. Dalenberg PhD, Scott F. Sorg PhD & Igor Grant MD
Pages: 24-43 | DOI: 10.1080/00952990.2016.1206113
An
initial fMRI study on neural correlates of prayer in members of Alcoholics Anonymous |
Marc Galanter MD, Zoran Josipovic PhD, Helen Dermatis PhD, Jochen Weber & Mary Alice Millard
Pages: 44-54 | DOI: 10.3109/00952990.2016.1141912
Long-term
follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson PhD, Albert Garcia-Romeu PhD & Roland R. Griffiths PhD
Pages: 55-60 | DOI: 10.3109/00952990.2016.1170135
Establishment
of an alcoholic fatty liver disease model in mice
Peizhu Tan MM, Huan Liang MD, Junhui Nie MB, Yan Diao MM, Qi He MM, Baoyu Hou MB, Tingting Zhao MB, Hui Huang MD, Yanze Li MD, Xu Gao MD, Lingyun Zhou MD & Ying Liu MD
Pages: 61-68 | DOI: 10.1080/00952990.2016.1217539
From
dispensed to disposed: evaluating the effectiveness of disposal programs through a comparison with prescription drug monitoring program data
Kathleen L. Egan MS, Eric Gregory EdD, CPS, Michael Sparks MA & Mark Wolfson PhD
Pages: 69-77 | DOI: 10.1080/00952990.2016.1240801
Palonosetron
and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study
Matthew J. Erlendson BA, Nicole D’Arcy MD, Ellen M. Encisco BA, Jeffrey J. Yu BS, Lorena Rincon-Cruz BS, Gary Peltz MD, PhD, J. David Clark MD & Larry F. Chu MD, MS
Pages: 78-86 | DOI: 10.1080/00952990.2016.1210614
Family
cohesion and pride, drinking and alcohol use disorder in Puerto Rico
Raul Caetano MD, PhD, Patrice A. C. Vaeth Dr PH & Glorisa Canino PhD
Pages: 87-94 | DOI: 10.1080/00952990.2016.1225073
Effect
of anticipatory stress on placebo alcohol consumption in a bar laboratory
Michael H. Bernstein & Mark D. Wood
Pages: 95-102 | DOI: 10.1080/00952990.2016.1209514
Marijuana
use and viral suppression in persons receiving medical care for HIV-infection
Chukwuemeka N. Okafor MPH, Zhi Zhou DDS, MPH, Larry E. Burrell II MS, Natalie E. Kelso MSW, Nicole E. Whitehead PhD, Jeffery S. Harman PhD, Christa L. Cook PhD, MSN & Robert L. Cook MD, MPH
Pages: 103-110 | DOI: 10.1080/00952990.2016.1191505
Online
and offline video game use in adolescents: measurement invariance and problem severity
Máté Smohai PhD, Róbert Urbán PhD, Mark D. Griffiths PhD, Orsolya Király PhD, Zsuzsanna Mirnics PhD, András Vargha DSc & Zsolt Demetrovics PhD
Pages: 111-116 | DOI: 10.1080/00952990.2016.1240798
Characteristics
associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting
Adriana M. Joseph MPH, Marc W. Manseau MD, MPH, Monique Lalane LCSW, Amit Rajparia MD & Crystal Fuller Lewis PhD
Pages: 117-122 | DOI: 10.1080/00952990.2016.1240799
Letter to the Editor
Discordant
reporting of nonmedical opioid use
Xiulu Ruan MD, Srinivas Chiravuri MD & Alan David Kaye MD, PhD
Pages: 123-124 | DOI: 10.1080/00952990.2016.1209515
Response
Discordant
reporting of nonmedical opioid use: reply to letter to the editor
Joseph J. Palamar PhD, MPH, Jenni Shearston BA & Chuck Cleland PhD
Pages: 125-126 | DOI: 10.1080/00952990.2016.1208211
Corrigenda
Corrigendum
Pages: 127-127 | DOI: 10.1080/00952990.2016.1277105